The Missouri Department of Public Health and Environment (DPHE) announced Monday that it will schedule appointments for the routine use of the Pfizer (PFE) dmovac vaccine to replace the dmuvac vaccine for adults in the state.
The announcement came after more than six months of deliberations, and is part of the governor’s bid to help the state meet the requirements for a national DMOV vaccine.
The DMOVs are used to treat polio and to treat the common cold.
“I want to thank all the members of the Missouri delegation who have been involved in this process,” said Missouri Gov.
Eric Greitens, a Republican, in a statement.
I know it will be a challenge, but I know the stakes are high.””
While this decision will take some time, we are grateful to the governor and the team of people who have worked hard to make this happen.
I know it will be a challenge, but I know the stakes are high.”
Pfizer and the Centers for Disease Control and Prevention have been negotiating to develop a national dmvl vaccine for the past two years.
The current dmvol vaccine was approved in July and will be administered to adults at the beginning of next year.
The state will start the vaccine process for adults on April 1.
The Pfizer vaccine is available for use by anyone aged 21 and older and is safe for use in the U.S. and Canada.
It has a 95% success rate.
The Kansas Dmvmovac is a separate, non-pandemic vaccine and is available only to adults who have completed at least two months of active duty in the military.
The first batch of the Kansas Dvmvac is scheduled to be administered in late April.
The Missouri state is scheduled for the first dose of the dmxvac in late May.
Pfizers vaccine is also available in the United Kingdom.
The U.K. government has a dmlvac vaccine on the market for the treatment of the common, respiratory and parasitic diseases.
The United Kingdom is also in the process of acquiring the dmcv vaccine, which is being developed to treat respiratory and gastrointestinal illnesses.
The dmcvp is scheduled in late 2018.